Roche (RHHBY) announced the completion of the acquisition of LumiraDx’s (LMDX) Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company’s innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organization. Through this acquisition, Roche complements its diagnostics portfolio with a simple-to-use platform that consolidates a wide range of immunoassay and clinical chemistry tests on a single instrument, with the future potential to expand into molecular testing. The solution will allow Roche to further expand its offering in decentralized patient care, and drive global access to timely and actionable diagnostic results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
- Roche price target raised to CHF 275 from CHF 230 at Barclays
- Roche price target raised to CHF 265 from CHF 215 at Deutsche Bank
- Roche sees 2024 core EPS growing in high single digit range
- Roche reports 1H core EPS CHF 10.23 vs. CHF 10.10 last year